Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,890.78
    +13.73 (+0.17%)
     
  • Bitcoin USD

    64,585.00
    +651.79 (+1.02%)
     
  • CMC Crypto 200

    1,374.32
    +61.69 (+4.94%)
     
  • S&P 500

    4,994.33
    -16.79 (-0.34%)
     
  • Dow

    37,936.17
    +160.79 (+0.43%)
     
  • Nasdaq

    15,441.27
    -160.22 (-1.03%)
     
  • Gold

    2,409.60
    +11.60 (+0.48%)
     
  • Crude Oil

    83.32
    +0.59 (+0.71%)
     
  • 10-Yr Bond

    4.6190
    -0.0280 (-0.60%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today

Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today

Shares of BioCryst (NASDAQ: BCRX), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. The FDA approved BioCryst's first drug, Orladeyo, for patients with hereditary angioedema last December. Independent new drug launches have a terrible tendency to miss expectations, so the stock market is extra jumpy about revenue figures right now.